Margetuximab: "Primary analysis (Oct-2018 cutoff): 24% risk reduction in centrally blinded PFS (HR 0.76, P=0.033)"; Breast cancer (Macrogenics) - Dec 12, 2019 - SABCS 2019: "2nd interim OS (Sep-2019 cutoff): favors margetuximab (mOS 21.6 vs 19.8 mos; HR=0.89, P=0.326)"
P3 data
|